Skip to main content
. 2016 Apr 21;7:152. doi: 10.3389/fimmu.2016.00152

Figure 1.

Figure 1

Clinical and preclinical therapies augmenting NK cells function. mAb (gray)-mediated blockade of the interaction between inhibitor receptors (in black) expressed on NK cells with the respective ligands on tumor cells (or suppressor cells) results in increased cytolytic potential of NK cells. ADCC therapy: binding of mAbs (red) to tumor-specific antigens (TSA) results in the activation of NK cells via the activation of the activating receptor CD16 (red).

HHS Vulnerability Disclosure